Skip to main content

Table 3 Effect of Euryale ferox salisb. seeds extract (EFx) during 120 min (2 h) on OGTT in normal and STZ induced diabetic (treated) rats

From: Antidiabetic, antioxidant, antihyperlipidemic effect of extract of Euryale ferox salisb. with enhanced histopathology of pancreas, liver and kidney in streptozotocin induced diabetic rats

Groups

Time (h)

0 h

0.5 h

1 h

1.5 h

2 h

Normal rats [untreated with dimethylsulfoxide, (DMSO)] Group 1

82.91 ± 0.3829a

95.60 ± 0.2651a

108.62 ± 0.3387a

117.67 ± 0.9812a

138.15 ± 0.4991a

Diabetic control (administered with Streptozotocin (STZ) Group 2

265.9 ± 0.9826b

278.2 ± 0.8519b

284.7 ± 0.2911b

279.1 ± 0.8171b

274.9 ± 0.3012b

Diabetic + (EFx) (100 mg/kg body weight) Group 3

235.0 ± 1.086

225.0 ± 0.8882

221.0 ± 0.2465

203.9 ± 0.8683

182.4 ± 0.2997

Diabetic + (EFx) (200 mg/kg body weight) Group 4

225.2 ± 0.9767

214.8 ± 0.8538

212.4 ± 0.2989

198.0 ± 0.6565

171.6 ± 0.4256

Diabetic + (EFx) (300 mg/kg body weight) Group 5

214.2 ± 1.263

211.5 ± 0.6072

202.8 ± 0.4556

185.7 ± 1.784

142.8 ± 0.7964**

Diabetic + (EFx) (400 mg/kg body weight) Group 6

203.1 ± 1.652

192.3 ± 0.5702

182.8 ± 0.3597

162.4 ± 0.4513*

88.45 ± 0.7672***

Diabetic + glibenclamide (1 mg/kg body weight) Group 7

198.3 ± 0.5980

182.4 ± 0.5737

170.9 ± 0.3304

141.7 ± 0.5050**

82.80 ± 0.5378***

  1. The data are expressed as mean ± SEM (n = number of animals in each group = 5). The comparisons has been made by one way ANOVA followed by Dunnent’s test.
  2. ns non-significant, STZ Streptozotocin.
  3. * p < 0.05 is considered as significant when compared to the control group (0 h).
  4. ** p < 0.001 is considered as very significant when compared to the control group (0 h).
  5. *** p < 0.001 is considered as extremely significant when compared to the control group (0 h).
  6. aCompared to diabetic control.
  7. bCompared to normal control.